We did have a short conversation at the end, but this is mostly the American Kratom Associations Presentation at Champs Trade Show in Las Vegas. https://vimeo.com/1190322917?share=copy&fl=sv&fe=ci

Key mentions I found: 1. Page 9 lists “kratom with high 7-hydroxymitragynine / 7-OH content” as an example of domestically marketed dangerous products, alongside tianeptine, mushroom edibles, and psychoactive hemp products. The word “7-hydroxymitragynine” appears misspelled there as “7-hydroxymitragyine.” 2. https://www.whitehouse.gov/releases/2026/05/2026-national-drug-control-strategy-released/Page 14 includes kratom under “Domestic Production” concerns, grouped with high-potency marijuana, hemp-derived psychoactive products like delta-8 THC, and “legal psychedelics.” 3. Page 33 says enforcement will focus on substances outside regulatory frameworks or sold illegally, including “dangerous substances like 7-hydroxymitragynine,” described as “an active component and potent opioid found in the kratom plant,” when illegally marketed or adulterated. 4. Page 34 has a full text box titled “Kratom Victim: it’s neither organic nor safe” and discusses Jordan McKibban. It says kratom sold in the U.S. can include “highly enriched levels of laboratory-made 7-OH” and references FDA warning letters against companies marketing 7-OH products. 5. Page 51 says treatment/diagnosis should account for new drugs, including “kratom products with high 7-OH levels.” 6. Pages 62, 64, and 67 connect high-7-OH kratom products to overdose response, breathing suppression, overdose fatalities, and naloxone planning. Page 62 also says CDC SUDORS data identified 995 overdose deaths with kratom or mitragynine detected in toxicology reports, which is detection language, not necessarily causation language. 7. Page 98 and Page 124 include a performance measure to increase FDA warning letters to companies selling unauthorized products containing Delta-8 THC, Kratom/7-OH, and other opioids. The target is 13 warning letters in 2026 and 18 in 2029. 8. Page 173 says smoke shops may sell products derived from kratom that “may contain 7-OH,” and importantly admits: kratom is a plant, products can be supplemented with synthetic 7-OH, and 7-OH is naturally found in kratom only in a small percentage. It also says HHS recommended classifying 7-OH as Schedule I in July 2025. 9. Pages 179, 184, 190, and 194 are mostly acronym/reference pages, including “7-OH: 7-hydroxymitragynine” and citations to FDA/HHS/CDPH materials.

This was such a wonderful day, September 13, 2016 https://youtu.be/UiMdC9rzDIU?si=6e3KELgFRxFHrQ7G

Quick recap The meeting focused on discussions about kratom regulation, industry challenges, and advocacy efforts. Christopher shared insights from a conversation with an addiction doctor who is interested in learning more about kratom as a leaf versus other products in the market. The group discussed recent news about a theft of $6,740 worth of kratom products, debated the effectiveness of fentanyl test strips, and examined the challenges of proper kratom education being restricted on social media platforms despite allowing other potentially harmful content. They also discussed the need for better regulation of kratom products, particularly addressing concerns about enhanced extracts like 7OH, and explored ways to present fiscal impact data to states considering bans. The conversation touched on personal experiences with medical cannabis and the importance of proper plant medicine usage, while emphasizing the need for proper education and regulation in the kratom industry. Summary Wi-Fi Coverage Discussion Meeting Christopher and Venus discussed Wi-Fi coverage issues at their location. Christopher explained his decision not to expand Wi-Fi to the office area and shared his positive experience with a Wi-Fi extender. They also briefly discussed a news article about a police officer who had stolen something other than Kratom. Kratom Theft and Enforcement Discussion Christopher and Venus discussed a recent theft of $6,740 worth of kratom tablets, with Christopher questioning the reported value given typical retail prices. They also discussed the challenges of drug enforcement and addiction treatment, including the limited effectiveness of fentanyl test strips as people often continue using contaminated drugs. Christopher shared a positive conversation with an addiction doctor who is open to learning about kratom as a leaf and other products in the market. Kratom Regulation and Advocacy Challenges Christopher and Venus discussed the changing landscape of drugs and chemicals, particularly the increased prevalence and abuse of enhanced Kratom products like 7OH. They highlighted the lack of awareness among consumers about different Kratom products and the challenges in providing education due to social media restrictions. Christopher expressed frustration over politicians' disregard for public opinion and evidence during hearings on Kratom regulation, attributing it to political agendas or ignorance. Venus noted that despite challenges, the advocacy efforts are growing louder.